In parallel dealmaking, Sun Pharmaceuticals announced plans to acquire Organon and expand its women’s health and biosimilars portfolio. The all-cash $11.75 billion transaction would make Sun one of the top players in women’s health, following Organon’s spinout from Merck. Deal details include an enterprise valuation of $11.75 billion, with the transaction priced at $14 per share and expected to close under standard regulatory review timelines. For Sun, the rationale is to add a portfolio with exposure beyond oncology and infectious disease, while for the sector it signals continued consolidation as big pharma seeks defensible franchises. Taken together with Lilly’s acquisition of Ajax, the headlines point to sustained capital deployment toward pipeline complements in therapeutic areas with identifiable unmet needs and clear commercial pathways.